Tirzepatide
FDA ApprovedTirzepatide
A dual GIP and GLP-1 receptor agonist. FDA approved for type 2 diabetes, with remarkable weight loss data showing up to 20% body weight reduction in trials.
Dose
Starting at 2.5 mg once weekly, escalating in 2.5 mg increments every 4 weeks to a maximum of 15 mg once weekly, based on tolerability and response.
Route
SubQ injection
Cycle
Ongoing as prescribed in research settings for chronic conditions.
Storage
Not applicable; typically supplied as a liquid solution.
What is Tirzepatide?
Tirzepatide is a novel synthetic peptide that functions as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual agonism mimics the effects of endogenous incretin hormones, leading to enhanced glucose-dependent insulin secretion, suppression of glucagon secretion, delayed gastric emptying, and reduced food intake through central appetite regulation. Originally approved for the treatment of type 2 diabetes, research has extensively documented its efficacy in significant body weight reduction, often surpassing that observed with selective GLP-1 receptor agonists. Its extended half-life allows for once-weekly subcutaneous administration, making it a prominent subject in metabolic research.
Key Benefits
- Superior weight reduction vs semaglutide in trials
- Blood sugar control
- Appetite suppression
- Cardiovascular benefits
- Improved insulin sensitivity
Mechanism of Action
- Dual GIP and GLP-1 receptor agonism
- Reduces appetite
- Slows gastric emptying
- Enhances insulin secretion
Best For
- Weight management research
- Metabolic health
- Type 2 diabetes research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
4813.5 g/mol
Length
39 amino acids
Type
Synthetic linear peptide, fatty acylated
Amino acid sequence
Y-A-E-G-T-F-I-S-D-Y-S-I-A-L-D-S-P-S-A-V-A-W-L-F-K-N-G-G-P-S-S-G-A-P-P-P-S-NH2 (Lys at position 20 is C18 fatty diacid modified)
Tirzepatide is a 39-amino acid synthetic peptide analog, incorporating an albumin-binding fatty diacid moiety at Lys20 for extended half-life.
Pharmacokinetics
Time to peak
8 to 24 hours
Half-life
120 h
Time to clear
Approximately 25 days (5 half-lives)
Based on pharmacokinetic studies in humans, typically reported in prescribing information and clinical trial publications.
Research Indications
Obesity and Overweight with Comorbidities
Extensively studied for significant and sustained body weight reduction in individuals with obesity or overweight and at least one weight-related comorbidity.
Non-alcoholic Steatohepatitis (NASH)
Investigated for its potential to improve liver histology and reduce liver fat due to its metabolic effects.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Initial Dose Titration for Weight Loss | 2.5 mg once weekly for 4 weeks, then increase to 5 mg once weekly for 4 weeks. | Once weekly | Subcutaneous injection |
| Maintenance Dosing for Optimal Glycemic Control and Weight Loss | Escalate dose in 2.5 mg increments every 4 weeks to 10 mg or 15 mg once weekly, based on tolerability and therapeutic response. | Once weekly | Subcutaneous injection |
| Assessment of Cardiovascular Outcomes | Individualized maintenance dose (e.g., 10 mg or 15 mg) once weekly, consistent with protocols. | Once weekly | Subcutaneous injection |
| Study of Gastrointestinal Side Effects Mitigation | Gradual dose escalation starting at 2.5 mg, with slower increases or extended periods at lower doses if needed for tolerability. | Once weekly | Subcutaneous injection |
Dose escalation is a common research protocol to assess tolerability and optimize therapeutic effect.
Peptide Interactions
- Use Caution
Insulin secretagogues (e.g., sulfonylureas)
Increased risk of hypoglycemia; a dose reduction of the insulin secretagogue may be necessary.
- Use Caution
Insulin
Increased risk of hypoglycemia; a dose reduction of insulin may be necessary.
- Monitor Combination
Oral medications with narrow therapeutic indices
Tirzepatide delays gastric emptying, which could affect the absorption of concomitantly administered oral medications. Monitoring for altered effects is commonly discussed.
- Use Caution
Oral contraceptives
Tirzepatide may reduce the effectiveness of oral contraceptives, particularly during the first month after initiation or dose escalation. Researchers often advise alternative or additional contraception.
- Avoid
Other GLP-1 Receptor Agonists
Concurrent use is not recommended due to overlapping mechanisms of action and potential for increased side effects without additional benefit.
How to Reconstitute
What to Expect
- Weeks 1-4: Initial improvements in blood glucose control and potential mild appetite suppression. Some individuals may experience gastrointestinal side effects.
- Weeks 5-12: Continued improvements in blood glucose and more noticeable reductions in appetite and food intake. Initial weight loss may become evident.
- Months 3-6: Substantial weight loss often observed, alongside sustained blood glucose regulation. Gastrointestinal side effects typically diminish.
- Months 6-12+: Ongoing weight management and metabolic benefits. Further weight reduction may occur, reaching study endpoints for maximum effect.
- Long-term research: Sustained improvements in cardiovascular risk markers and A1C levels, as observed in extended clinical trials.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Very Common | Mild-Moderate |
| Vomiting | Common | Mild |
| Diarrhea | Common | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.